Bibliography
- RYBAK M: Therapeutic options for Gram-positive infections. .J. Hosp. Infect. (2001) 49 (Suppl.A) : S25–532.
- DIEKEMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358:1975–1982.
- SMITH TL, PEARSON ML, WILCOX KR et al: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl. I Med. (1999) 340:493–501.
- PERL TM: The threat of vancomycin resistance. Am. J. Med. (1999) 106(5A):265-375 and 48S–52S.
- HIRAMATSU K: The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. (1998) 104:7S–10S.
- TENOVER FC, LANCASTER MV, HILL BC et al: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. ./. Clin. Microbial. (1998) 36:1020–1027.
- THORNSBERRY C, SAHM DF, KELLY LJ et al: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumaniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999–2000. Clin. Infect. Dis. (2002) 34\(Supp1.1):54–516.
- LINDEN PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs (2002) 62(3):425–441.
- ABBANAT D, MACIELAG M, BUSH K: Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs (2003) 12(3):379–399.
- ••An excellent review on new developmentalanti-Gram-positive agents currently undergoing clinical trials in humans.
- SING MP, JANSO JE, LUCKMAN SW, GREENSTEIN M: AC98, new cyclic glycopeptide antibiotics: mechanism of action. Abstracts of 41st Intersci. Conf Antimicrob. Agents Chemother. (2001) F-1149:230.
- DUSHIN RG, WANG T, FORTIER G et al: Synthesis of AC98-6446, a semisynthetic mannopeptimycin derivative. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-352:179.
- PETERSEN PJ, LABTHAVIKUL P, WANG T, DUSHIN RG, BRADFORD P: In vitro comparative activity of AC98-6446, a novel semisynthetic cyclic glycopeptide derivative of the natural product AC98-1, and other antimicrobial agents against Gram-positive clinical isolates. Abstracts of 42nd Intersci. Conf. Antimicrob. Agents Chemother. (2002) F-353:179.
- PETERSEN PJ, HARTMAN H, WANG T, DUSHIN RG, BRADFORD P: Time kill kinetics and postantibiotic effects (PAE) of the AC98 novel semisynthetic cyclic glycopeptide antibiotic derivative AC98-6446. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-354:179.
- LABTHAVIKUL P, PETERSEN PJ, WANG TZ, DUSHIN RG, BRADFORD PA: Effect of inoculum, pH and biofilm on the in vitro activity of AC98-6446 the novel semi-synthetic cyclic glycopeptide of AC98. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-355:179.
- MURPHY TM, LENOY EB, YOUNG M, WEISS WJ: In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental models of infection. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-356:180.
- HE H, WILLIAMSON RT, SHEN B et al.:Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygrascopicus, LL-AC98. J. Am. Chem. Soc. (2002) 124:9729–9736.
- MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8:1759–1773.